SarcopeniaDEMGUTSNCT06545123
Distinct Exercise Modalities on Gut Microbiome
A study testing Concurrent exercise training in people with Sarcopenia and Older Adults, run by Faculty of Sports- Research Center in Physical Activity, Health and Leisure at 1 site in Portugal.
Trial summary
Sarcopenia is a multifactorial muscular disease with detrimental clinical consequences, impairing physical function, functional independence, quality of life, need for long-term care and premature mortality. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Sarcopenia, Older Adults
- What is being tested?
- Concurrent exercise training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 69 participants
- Where
- 1 sitePortugal
- Study dates
- 1 Sep 2024to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: ≥ 60 years old
- Sex: Men and women
- Medical History: Objective indicators of sarcopenia- Handgrip strength: men < 27 kg and women < 16 kg; 4-m gait speed ≤ 0.8 m/s; Short Physical Performance Battery ≤ 8-point score; Chair stand test > 15 s; Time-up-go ≥ 20 s.
- Physical Inactivity: International Physical Activity Questionnaire (IPAQ)- Portuguese version ≤ 150 minutes/week of moderate physical activity
- Willingness to participate in all study procedures regardless of possible group allocation.
Who cannot join
- Failure to provide consent.
- Uncontrolled Hypertension: SBP> 180 mmHg or DBP> 110 mmHg.
- History of coronary artery stenosis (>50%).
- Heart Failure: Ejection fraction < 50%.
- History of syncope at exertion.
- History of hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, dilated cardiomyopathy or evidence in the previous 6 months of myocarditis or pericarditis.
Show all 13Show fewer
- Severe valvular heart disease.
- Chronic kidney disease stage ≥ 4,8.
- Chronic Obstructive Pulmonary Disease stage ≥ 3,9.
- Musculoskeletal or neurodegenerative conditions that hinder exercise engagement.
- Current participation in another structured exercise training program.
- Inability to commit to study procedures or the exercise intervention throughout the study period.
- Other condition or concern precluding safe participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Portugal1 site, 1 recruiting
- Recruiting
Faculty of Sports
Porto
Jorge Mota, 351 220425273, jmota@fade.up.pt
About this study
Official title: Unraveling the Impact of Distinct Exercise Modalities on GUT Microbiome and Gut-derived Metabolites in Older Adults with Sarcopenia
Sarcopenia is a multifactorial muscular disease with detrimental clinical consequences, impairing physical function, functional independence, quality of life, need for long-term care and premature mortality. The development of sarcopenia is influenced by a complex interaction of multiple environmental and endogenous factors. However, to date, these complex mechanisms were unable to fully explain sarcopenia adverse health outcomes on skeletal muscle mass and function in older adults. Recently, the gut microbiome and its gut-derived metabolites have emerged as a key player in sarcopenia, with evidence suggesting that influence many underlying pathophysiological mechanisms (i.e., immune and inflammation system, anabolic resistance, insulin sensitivity, and energy production) that are involved in the development of sarcopenia. Current treatment guidelines of sarcopenia reinforce the role of exercise training, particularly resistance training to prevent adverse health outcomes. Exercise also stimulates favorable changes in gut microbiome composition and function, leading to host health benefits, regardless of nutrition. Nonetheless, the effects of exercise training on gut microbiome in patients with sarcopenia remains unclear, with existing evidence derived mainly from observational studies. In addition, the available evidence suggests that different types of exercise modalities may elicit distinct changes in gut microbiota composition but, to date, no study specifically addressed the optimal type of exercise modality in older adults considering the impact of gut microbiota composition or of gut-derived metabolites. Thus, despite the growing body of literature on the gut-muscle axis and sarcopenia, evidence from comparative studies focused on different exercise training regimens with a randomized controlled trial design in the impact of gut microbiota on skeletal muscle mass and function in sarcopenic patients is still lacking. Given that aerobic and resistance exercise stimulate different bioenergetic mechanisms and metabolic signaling pathways, we hypothesize that gut microbiome composition may be differently modulated by these distinct exercise regimens and that differently impact skeletal muscle mass and function, and physical performance in older adults. Leveraging current recruitment, logistics and human resources from a community exercise training program and the internal institutional collaborations, the investigative team will build a consecutive line of research to fill this literature gap and explore the impact of different exercise regimens on gut microbiome composition and gut-derived metabolites in these patients. The research team will start with a pilot single center 3-parallel arm open-label randomize control trial. Participants that meet the inclusion/exclusion criteria will be randomly assigned to: i) moderate aerobic exercise (AER); ii) resistance exercise (RES); or iii) concurrent exercise training (RES+AER). Participants in the experimental groups will engage in a supervised center-based exercise intervention (12-weeks, 3d/w, 60min/d). All participants will be assessed at i) baseline, ii) end of intervention (14 weeks) and iii) at close-out (26-weeks). The primary outcome will be the change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks). Secondary outcomes include 1) change of Faecalibacterium prausnitzii relative abundance at close-out (26 weeks); 2) change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up. A set of complementary outcomes will also be assessed to broadly characterize the impact of each exercise intervention, including body composition, skeletal muscle function, functional performance and general gut microbiome composition. Other important confounding outcomes will be evaluated, including nutritional intake, daily physical activity, medication and supplementation use, and associated comorbidities. In the long term, the study team expects to contribute to clinical guidance and exercise prescription in older adults with sarcopenia using an evidence-based approach by exploring the optimal exercise mode to elicit favorable gut and skeletal muscle health benefits.
Read the detailed description
The gut microbiome is an important regulator of metabolism and has recently emerged as a relevant contributor to musculoskeletal health and disease, specifically to changes in skeletal muscle mass and function through a communication axis known as the gut-muscle axis. This posited gut-muscle communication pathway raises the attractive possibility that by manipulating the gut microbiota composition and function, scientists could mediate changes in skeletal muscle health and prevent sarcopenia adverse health outcomes. Thus, therapeutic strategies developed to modulate gut microbiome composition may have clinically meaningful implications in age-related muscle loss and physical function decline. Exercise has been shown to modulate the gut microbiome in older adults, but the evidence from well-designed randomized clinical trials is scarce. On the one hand, current guidelines recommend resistance training to reduce age-related skeletal muscle loss and physical function impairment. Still, on the other hand, aerobic exercise training is associated with increased microbiota diversity and an increase in SCFA-producing taxa, which has been linked to skeletal muscle health benefits and improved function. Given that these two exercise training regimens have different bioenergetic pathways, the study team hypothesized that each regimen promotes distinct alterations in gut microbiome composition. In contrast, combining both forms of exercise (resistance + aerobic) may lead to an added effect. Therefore, unraveling the impact of these exercise regimens on the gut microbiome is crucial to fill this relevant knowledge gap and to help clarify the optimal exercise regimen to manage sarcopenia. The research team long-term goal is to develop a consecutive line of research to explore the impact of these different exercise training regimens (i.e., resistance, aerobic, and concurrent exercise training) on gut microbiome composition and gut-derived metabolites and investigate its effects on skeletal muscle mass and function in older adults with sarcopenia. Methodology: Study design: This project will use a pilot 3-arm open-label randomized controlled trial (RCT), designed to evaluate the impact of distinct exercise training regimens on gut microbiome composition in older adults (age ≥ 60 years old) with sarcopenia. Methods: This study will use the recruitment, logistic and material resources from a community exercise program. Those who met our pre-screening criteria will be contacted by a study member, exposing the study's purposes, procedures, risk-discomforts, and benefits. Participants who agree will be invited to an in-person medical screening visit to assess the final inclusion/exclusion criteria and to provide their written informed consent (before enrollment). In this visit, volunteers will be evaluated through clinical examination, medication history, and a handgrip dynamometry test (an objective indicator of sarcopenia) to assess participants eligibility. Those who meet all inclusion/exclusion criteria will be randomly assigned (N= 69; 23/group) to three distinct exercise training programs: i) aerobic exercise (AER) training, ii) resistance exercise (RES), or iii) concurrent training (RES+AER). This project aims to randomize up to n=69 participants (n=23 / group) based on evidence from a recent systematic review with meta-analysis (11). Participants will engage in supervised center-based exercise interventions (12 weeks, 3d/w, 60min/d) consisting of either moderate aerobic training [60-70% HRmax], or resistance exercise [8 exercises/major muscle groups; 6-12 reps; 60-75% 1RM] or a combination of both (RES+AER). Assessments: All participants will be assessed at: i) baseline; ii) end of intervention (14-weeks); and iii) at close-out (26-weeks). Total length of the study is 26-weeks. At each study visit, participants will complete a skeletal muscle strength test, physical performance tests, assessment of body composition and provide a fasted blood, urine and fecal sample. Other important confounding variables will also be recorded including nutritional intake (using a 3-day diary), daily physical activity (using a physical activity tracker- wrist Fitbit), medication and supplementation use and associated comorbidities (assessed through medical and medication history questionnaire). Per the study design, the study team will also evaluate: a) retention and attrition rates; b) adherence to exercise intervention; c) safety; d) intervention effect on dependent outcomes. The success of recruitment and retention rates will be measured by the number of participants recruited, the number of drop-outs and losses to follow-up throughout the trial. Adherence to the exercise intervention will be carefully documented by study staff and will be measured by the number of sessions attended. Safety will be measured by the number and/or seriousness of adverse events attributable to the intervention and monitored and recorded by study staff throughout the trial. Objectives: Primary aim: The primary outcome will be the change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks). Secondary outcomes include: 1) change of Faecalibacterium prausnitzii relative abundance at close-out (26-weeks); 2) change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up. Secondary aim: A set of complementary outcomes will also be assessed to broadly characterize the impact of each exercise intervention, including body composition, skeletal muscle function, functional performance and general gut microbiome composition. This broad set of outcomes will allow a comprehensive evaluation of the impact of these distinct exercise regimens on gut microbiota and on several health outcomes that are crucial for modulating gut microbiome and sarcopenia and may point to other mechanistic links that are currently undetermined. Expected Outcomes: The investigative team hypothesized that combining aerobic and resistance training will have a greater impact on the gut microbiome, specifically in increasing the relative abundance of Faecalibacterium prausnitzii and other SCFA-producing bacterial strains, an increase in skeletal muscle mass and strength, as well as enhanced physical performance measures in the concurrent exercise training group.
- Conditions
- Sarcopenia, Older Adults
- Being tested
- Concurrent exercise training
- Keywords
- Gut Microbiome, Exercise, Metabolomics, Physical function
- Medical subject headings
- Sarcopenia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Concurrent exercise trainingBehavioural
The experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists
| Study group | Role | What they receive |
|---|---|---|
| Resistance exercise training | Active comparator | The main part of RES group session will include free weights, weight machines and calisthenics. Loads will be set and adjusted based on 1 repetition maximum (1RM) method (details are described in Table 2). Exercises will be standardized but exercises may be adapted according to participants limitations. For RES group, the intervention was divided in 2 periods: a) 3- weeks adaptation phase (7-10 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (8 exercises; 3 sets; 6-12 reps; 70% 1RM; intensity measured by the rate of perceived exertion (RPE) 3-5 on category ratio 10 (CR10) scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises) as recommended (29). Each session will aim at two anatomical regions (upper limbs, torso, back, lower limbs). Receives: Behavioral: Concurrent exercise training |
| Aerobic exercise training | Active comparator | The main part of AER group sessions will include treadmill, stationary and elliptical bikes. The intensity throughout these sessions will be measured by heart rate maximum (HRmax) and by RPE 3-5 on CR10 scale progressing to RPE 6-8. The main part of AER group was divided in 3 periods; a) from week 1-2 (50% HRmax: 3x15 min+3min rest); b) week 3-4 (60% HRmax: 2x23min+5min rest); c) week > 5 (70% HRmax: continuous). Receives: Behavioral: Concurrent exercise training |
| Concurrent exercise training | Active comparator | The main part of RES+AER group sessions will combine both exercise training protocols. The main parts of this group will start with resistance training using weights, weight machines and calisthenics combined with a main part of moderate aerobic exercises in the treadmill, stationary and elliptical bikes. This intervention was divided into 2 phases: a) a 3-week adaptation period (4-6 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (4 exercises; 3 sets; 6-12 reps; 60-70% 1RM; intensity measured by the RPE 3-5 on CR10 scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises). Afterward, the moderate aerobic exercise training part will include three phases: 50% HRmax: 1x15 min); b) week 3-4 (60% HRmax: 1x23min); c) week > 5 (70% HRmax: continuous). Receives: Behavioral: Concurrent exercise training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria
The primary outcome will be the percent change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks) using next generation sequencing on faecal samples
Measured: 14-weeks
Secondary outcomes (2)
Percent change of Faecalibacterium prausnitzii relative abundance at close-out
Percent change of Faecalibacterium prausnitzii relative abundance at close-out (26-weeks)using next generation sequencing on faecal samples;
Measured: 26- weeks
Percent change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up
Percent change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention using next generation sequencing on faecal samples
Measured: 26- weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2024
- Study start1 Sep 2024
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants that meet the inclusion/exclusion criteria will be randomly assigned to: i) moderate aerobic exercise (AER); ii) resistance exercise (RES); or iii) concurrent exercise training (RES+AER).
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 69 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Faculty of Sports- Research Center in Physical Activity, Health and Leisure
- Sponsor type
- University, hospital or other
- Collaborators
- Unit for Multidisciplinary Research in Biomedicine
- Responsible party
- Sponsor
- Investigators
- Liliana C. Baptista, PhD, Principal investigator, Faculty of Sport, University of Porto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06545123
- Sponsor's protocol ID
- CEFADE 04 2024
- Acronym
- DEMGUTS
- Status last verified
- Feb 2025
- First submitted
- 20 Jul 2024
- Last updated
- 4 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This project contemplates a plan to disseminate knowledge using specific methods and actions, distinct digital platforms and directed to different audiences. The goal is to disseminate the novel findings that may result from this project as soon as possible upon completion and make them publicly available to all that may benefit with it. As soon as the last participant finishes his last assessment visit, the study team members will start to adequately analyze the study data. The study team will prepare abstracts and manuscripts for publication. Preliminary results that may seem adequate for scientific meetings will be prepared in accordance and presented at national or international relevant conferences.
Publications
Merelim AS, Zacca R, Moreira-Goncalves D, Costa PP, Baptista LC. Distinct exercise modalities on GUT microbiome in sarcopenic older adults: study protocol of a pilot randomized controlled trial. Front Med (Lausanne). 2025 Mar 5;12:1504786. doi: 10.3389/fmed.2025.1504786. eCollection 2025.
PubMed 40109720
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Unraveling the Impact of Distinct Exercise Modalities on GUT Microbiome and Gut-derived Metabolites in Older Adults with Sarcopenia
- ClinicalTrials.gov ID
- NCT06545123
- Acronym / sponsor ID
- DEMGUTS / CEFADE 04 2024
- Conditions
- Sarcopenia, Older Adults
- Keywords
- Gut Microbiome, Exercise, Metabolomics, Physical function
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 69 participants (estimated)
- Lead sponsor
- Faculty of Sports- Research Center in Physical Activity, Health and LeisureUniversity, hospital or other
- Collaborators
- Unit for Multidisciplinary Research in Biomedicine
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 9 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sarcopenia is a multifactorial muscular disease with detrimental clinical consequences, impairing physical function, functional independence, quality of life, need for long-term care and premature mortality. The development of sarcopenia is influenced by a complex interaction of multiple environmental and endogenous factors. However, to date, these complex mechanisms were unable to fully explain sarcopenia adverse health outcomes on skeletal muscle mass and function in older adults. Recently, the gut microbiome and its gut-derived metabolites have emerged as a key player in sarcopenia, with evidence suggesting that influence many underlying pathophysiological mechanisms (i.e., immune and inflammation system, anabolic resistance, insulin sensitivity, and energy production) that are involved in the development of sarcopenia. Current treatment guidelines of sarcopenia reinforce the role of exercise training, particularly resistance training to prevent adverse health outcomes. Exercise also stimulates favorable changes in gut microbiome composition and function, leading to host health benefits, regardless of nutrition. Nonetheless, the effects of exercise training on gut microbiome in patients with sarcopenia remains unclear, with existing evidence derived mainly from observational studies. In addition, the available evidence suggests that different types of exercise modalities may elicit distinct changes in gut microbiota composition but, to date, no study specifically addressed the optimal type of exercise modality in older adults considering the impact of gut microbiota composition or of gut-derived metabolites. Thus, despite the growing body of literature on the gut-muscle axis and sarcopenia, evidence from comparative studies focused on different exercise training regimens with a randomized controlled trial design in the impact of gut microbiota on skeletal muscle mass and function in sarcopenic patients is still lacking. Given that aerobic and resistance exercise stimulate different bioenergetic mechanisms and metabolic signaling pathways, we hypothesize that gut microbiome composition may be differently modulated by these distinct exercise regimens and that differently impact skeletal muscle mass and function, and physical performance in older adults. Leveraging current recruitment, logistics and human resources from a community exercise training program and the internal institutional collaborations, the investigative team will build a consecutive line of research to fill this literature gap and explore the impact of different exercise regimens on gut microbiome composition and gut-derived metabolites in these patients. The research team will start with a pilot single center 3-parallel arm open-label randomize control trial. Participants that meet the inclusion/exclusion criteria will be randomly assigned to: i) moderate aerobic exercise (AER); ii) resistance exercise (RES); or iii) concurrent exercise training (RES+AER). Participants in the experimental groups will engage in a supervised center-based exercise intervention (12-weeks, 3d/w, 60min/d). All participants will be assessed at i) baseline, ii) end of intervention (14 weeks) and iii) at close-out (26-weeks). The primary outcome will be the change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks). Secondary outcomes include 1) change of Faecalibacterium prausnitzii relative abundance at close-out (26 weeks); 2) change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up. A set of complementary outcomes will also be assessed to broadly characterize the impact of each exercise intervention, including body composition, skeletal muscle function, functional performance and general gut microbiome composition. Other important confounding outcomes will be evaluated, including nutritional intake, daily physical activity, medication and supplementation use, and associated comorbidities. In the long term, the study team expects to contribute to clinical guidance and exercise prescription in older adults with sarcopenia using an evidence-based approach by exploring the optimal exercise mode to elicit favorable gut and skeletal muscle health benefits.
Detailed description
The gut microbiome is an important regulator of metabolism and has recently emerged as a relevant contributor to musculoskeletal health and disease, specifically to changes in skeletal muscle mass and function through a communication axis known as the gut-muscle axis. This posited gut-muscle communication pathway raises the attractive possibility that by manipulating the gut microbiota composition and function, scientists could mediate changes in skeletal muscle health and prevent sarcopenia adverse health outcomes. Thus, therapeutic strategies developed to modulate gut microbiome composition may have clinically meaningful implications in age-related muscle loss and physical function decline. Exercise has been shown to modulate the gut microbiome in older adults, but the evidence from well-designed randomized clinical trials is scarce. On the one hand, current guidelines recommend resistance training to reduce age-related skeletal muscle loss and physical function impairment. Still, on the other hand, aerobic exercise training is associated with increased microbiota diversity and an increase in SCFA-producing taxa, which has been linked to skeletal muscle health benefits and improved function. Given that these two exercise training regimens have different bioenergetic pathways, the study team hypothesized that each regimen promotes distinct alterations in gut microbiome composition. In contrast, combining both forms of exercise (resistance + aerobic) may lead to an added effect. Therefore, unraveling the impact of these exercise regimens on the gut microbiome is crucial to fill this relevant knowledge gap and to help clarify the optimal exercise regimen to manage sarcopenia. The research team long-term goal is to develop a consecutive line of research to explore the impact of these different exercise training regimens (i.e., resistance, aerobic, and concurrent exercise training) on gut microbiome composition and gut-derived metabolites and investigate its effects on skeletal muscle mass and function in older adults with sarcopenia. Methodology: Study design: This project will use a pilot 3-arm open-label randomized controlled trial (RCT), designed to evaluate the impact of distinct exercise training regimens on gut microbiome composition in older adults (age ≥ 60 years old) with sarcopenia. Methods: This study will use the recruitment, logistic and material resources from a community exercise program. Those who met our pre-screening criteria will be contacted by a study member, exposing the study's purposes, procedures, risk-discomforts, and benefits. Participants who agree will be invited to an in-person medical screening visit to assess the final inclusion/exclusion criteria and to provide their written informed consent (before enrollment). In this visit, volunteers will be evaluated through clinical examination, medication history, and a handgrip dynamometry test (an objective indicator of sarcopenia) to assess participants eligibility. Those who meet all inclusion/exclusion criteria will be randomly assigned (N= 69; 23/group) to three distinct exercise training programs: i) aerobic exercise (AER) training, ii) resistance exercise (RES), or iii) concurrent training (RES+AER). This project aims to randomize up to n=69 participants (n=23 / group) based on evidence from a recent systematic review with meta-analysis (11). Participants will engage in supervised center-based exercise interventions (12 weeks, 3d/w, 60min/d) consisting of either moderate aerobic training [60-70% HRmax], or resistance exercise [8 exercises/major muscle groups; 6-12 reps; 60-75% 1RM] or a combination of both (RES+AER). Assessments: All participants will be assessed at: i) baseline; ii) end of intervention (14-weeks); and iii) at close-out (26-weeks). Total length of the study is 26-weeks. At each study visit, participants will complete a skeletal muscle strength test, physical performance tests, assessment of body composition and provide a fasted blood, urine and fecal sample. Other important confounding variables will also be recorded including nutritional intake (using a 3-day diary), daily physical activity (using a physical activity tracker- wrist Fitbit), medication and supplementation use and associated comorbidities (assessed through medical and medication history questionnaire). Per the study design, the study team will also evaluate: a) retention and attrition rates; b) adherence to exercise intervention; c) safety; d) intervention effect on dependent outcomes. The success of recruitment and retention rates will be measured by the number of participants recruited, the number of drop-outs and losses to follow-up throughout the trial. Adherence to the exercise intervention will be carefully documented by study staff and will be measured by the number of sessions attended. Safety will be measured by the number and/or seriousness of adverse events attributable to the intervention and monitored and recorded by study staff throughout the trial. Objectives: Primary aim: The primary outcome will be the change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks). Secondary outcomes include: 1) change of Faecalibacterium prausnitzii relative abundance at close-out (26-weeks); 2) change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up. Secondary aim: A set of complementary outcomes will also be assessed to broadly characterize the impact of each exercise intervention, including body composition, skeletal muscle function, functional performance and general gut microbiome composition. This broad set of outcomes will allow a comprehensive evaluation of the impact of these distinct exercise regimens on gut microbiota and on several health outcomes that are crucial for modulating gut microbiome and sarcopenia and may point to other mechanistic links that are currently undetermined. Expected Outcomes: The investigative team hypothesized that combining aerobic and resistance training will have a greater impact on the gut microbiome, specifically in increasing the relative abundance of Faecalibacterium prausnitzii and other SCFA-producing bacterial strains, an increase in skeletal muscle mass and strength, as well as enhanced physical performance measures in the concurrent exercise training group.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Participants that meet the inclusion/exclusion criteria will be randomly assigned to: i) moderate aerobic exercise (AER); ii) resistance exercise (RES); or iii) concurrent exercise training (RES+AER).
| Arm | Type | Receives |
|---|---|---|
| Resistance exercise training | Active comparator | Behavioral: Concurrent exercise trainingThe main part of RES group session will include free weights, weight machines and calisthenics. Loads will be set and adjusted based on 1 repetition maximum (1RM) method (details are described in Table 2). Exercises will be standardized but exercises may be adapted according to participants limitations. For RES group, the intervention was divided in 2 periods: a) 3- weeks adaptation phase (7-10 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (8 exercises; 3 sets; 6-12 reps; 70% 1RM; intensity measured by the rate of perceived exertion (RPE) 3-5 on category ratio 10 (CR10) scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises) as recommended (29). Each session will aim at two anatomical regions (upper limbs, torso, back, lower limbs). |
| Aerobic exercise training | Active comparator | Behavioral: Concurrent exercise trainingThe main part of AER group sessions will include treadmill, stationary and elliptical bikes. The intensity throughout these sessions will be measured by heart rate maximum (HRmax) and by RPE 3-5 on CR10 scale progressing to RPE 6-8. The main part of AER group was divided in 3 periods; a) from week 1-2 (50% HRmax: 3x15 min+3min rest); b) week 3-4 (60% HRmax: 2x23min+5min rest); c) week > 5 (70% HRmax: continuous). |
| Concurrent exercise training | Active comparator | Behavioral: Concurrent exercise trainingThe main part of RES+AER group sessions will combine both exercise training protocols. The main parts of this group will start with resistance training using weights, weight machines and calisthenics combined with a main part of moderate aerobic exercises in the treadmill, stationary and elliptical bikes. This intervention was divided into 2 phases: a) a 3-week adaptation period (4-6 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (4 exercises; 3 sets; 6-12 reps; 60-70% 1RM; intensity measured by the RPE 3-5 on CR10 scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises). Afterward, the moderate aerobic exercise training part will include three phases: 50% HRmax: 1x15 min); b) week 3-4 (60% HRmax: 1x23min); c) week > 5 (70% HRmax: continuous). |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age: ≥ 60 years old
- Sex: Men and women
- Medical History: Objective indicators of sarcopenia- Handgrip strength: men < 27 kg and women < 16 kg; 4-m gait speed ≤ 0.8 m/s; Short Physical Performance Battery ≤ 8-point score; Chair stand test > 15 s; Time-up-go ≥ 20 s.
- Physical Inactivity: International Physical Activity Questionnaire (IPAQ)- Portuguese version ≤ 150 minutes/week of moderate physical activity
- Willingness to participate in all study procedures regardless of possible group allocation.
Key exclusion criteria (13 listed)
- Failure to provide consent.
- Uncontrolled Hypertension: SBP> 180 mmHg or DBP> 110 mmHg.
- History of coronary artery stenosis (>50%).
- Heart Failure: Ejection fraction < 50%.
- History of syncope at exertion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Concurrent exercise trainingThe experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists | Behavioural | Aerobic exercise training, Concurrent exercise training, Resistance exercise training |
Primary outcome
Percent change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria
Time frame: 14-weeks
The primary outcome will be the percent change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria after the intervention (14-weeks) using next generation sequencing on faecal samples
2 secondary outcomes
Percent change of Faecalibacterium prausnitzii relative abundance at close-out
Time frame: 26- weeks
Percent change of relative abundance of Lactobacillus and Bifidobacterium genera after the intervention and at the end of the follow-up
Time frame: 26- weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2025.
- Derived from this study: PubMed 40109720Merelim AS, Zacca R, Moreira-Goncalves D, Costa PP, Baptista LC. Distinct exercise modalities on GUT microbiome in sarcopenic older adults: study protocol of a pilot randomized controlled trial. Front Med (Lausanne). 2025 Mar 5;12:1504786. doi: 10.3389/fmed.2025.1504786. eCollection 2025.
- Individual participant dataSharing planned: No. This project contemplates a plan to disseminate knowledge using specific methods and actions, distinct digital platforms and directed to different audiences. The goal is to disseminate the novel findings that may result from this project as soon as possible upon completion and make them publicly available to all that may benefit with it. As soon as the last participant finishes his last assessment visit, the study team members will start to adequately analyze the study data. The study team will prepare abstracts and manuscripts for publication. Preliminary results that may seem adequate for scientific meetings will be prepared in accordance and presented at national or international relevant conferences.
Related trials for Sarcopenia
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
Not yet recruiting
PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Frailty, Sarcopenia
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Recruiting
Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.
Frailty/Sarcopenia, Frailty in Older Adults
Not yet recruiting
Creatine and Muscle Health in Madrid's Walking Footballers.
Muscle Adaptation, Body Composition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Liliana C. Baptista, PhD principal investigator
Faculty of Sport, University of Porto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Concurrent exercise training in people with Sarcopenia and Older Adults, run by Faculty of Sports- Research Center in Physical Activity, Health and Leisure at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Liliana C. Baptista, PhD (+351 220 425 239, lbaptista@fade.up.pt), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change in the relative abundance of Faecalibacterium prausnitzii and other SCFA producing bacteria (time frame: 14-weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06545123, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2025.